InnotiveDx Secures £1 Million Grant to Enhance UTI Diagnostic Technology
Innotive Diagnostics (InnotiveDx) has announced a remarkable achievement; it has been awarded a substantial grant of £1 million from PACE (Pathways to Antimicrobial Clinical Efficacy). This funding is aimed at propelling the development of InnotiveDx's rapid urinary infection diagnostic system, specifically focusing on its innovative test known as InnotiveUTI. Through strategic collaboration, PACE aims to tackle the growing issue of antimicrobial resistance (AMR) by supporting pioneering projects like those from InnotiveDx.
The acute need for effective management of urinary infections is underscored by data reflecting that these infections affect hundreds of millions globally every year. They account for over 20% of antibiotic prescriptions, representing a significant factor contributing to AMR and unplanned hospital admissions, which impose billions in costs to health systems across the world.
InnotiveDx's proprietary technology for diagnosing urinary infections has demonstrated a remarkable ability to provide highly accurate bacterial identification and antibiotic susceptibility testing (AST) results in under 60 minutes. Impressively, this technology has exhibited laboratory test accuracy exceeding 96% during blind assessments. With this grant, InnotiveDx will conduct extensive evaluations to solidify the accuracy and reliability of fully operational and automated prototypes using thousands of clinical samples before transitioning into a pilot clinical study in real-world settings.
James Mainwaring, Chief Commercial and Operating Officer of InnotiveDx, expressed his enthusiasm regarding the grant, stating, "We are thrilled to have secured this £1 million PACE grant; it serves as a tremendous validation of our technology, our vision, and the hard work our team has dedicated since the firm's inception. AMR poses one of humanity's most pressing challenges, and we are eager to address this issue in collaboration with PACE and like-minded enterprises within its portfolio."
The program director of PACE, Dr. Beverley Isherwood, applauded InnotiveDx's efforts, remarking, "Congratulations to Innotive Diagnostics! We are pleased to welcome them into the PACE portfolio following a highly competitive funding call for diagnostics. PACE will support InnotiveDx in advancing InnotiveUTI through a collaborative approach, assisting them in generating essential validation data required for further development, financing, and investment for their project."
InnotiveDx is an innovative in vitro diagnostics company focusing on the progression of cutting-edge diagnostic systems, including the InnotiveUTI test that provides comprehensive bacterial identification and AST results at the point of care in just 60 minutes—a service that is currently lacking in many healthcare settings.
PACE stands as one of the UK’s largest public-private initiatives, a collaboration involving Innovate UK, LifeArc, and Medicines Discovery Catapult, dedicated to the early-stage development of antimicrobial drugs and diagnostics. This partnership reflects the collective commitment to revolutionize how urinary tract infections are diagnosed and treated in the face of rising antimicrobial resistance, ensuring timely and accurate interventions for millions affected worldwide.
The acute need for effective management of urinary infections is underscored by data reflecting that these infections affect hundreds of millions globally every year. They account for over 20% of antibiotic prescriptions, representing a significant factor contributing to AMR and unplanned hospital admissions, which impose billions in costs to health systems across the world.
InnotiveDx's proprietary technology for diagnosing urinary infections has demonstrated a remarkable ability to provide highly accurate bacterial identification and antibiotic susceptibility testing (AST) results in under 60 minutes. Impressively, this technology has exhibited laboratory test accuracy exceeding 96% during blind assessments. With this grant, InnotiveDx will conduct extensive evaluations to solidify the accuracy and reliability of fully operational and automated prototypes using thousands of clinical samples before transitioning into a pilot clinical study in real-world settings.
James Mainwaring, Chief Commercial and Operating Officer of InnotiveDx, expressed his enthusiasm regarding the grant, stating, "We are thrilled to have secured this £1 million PACE grant; it serves as a tremendous validation of our technology, our vision, and the hard work our team has dedicated since the firm's inception. AMR poses one of humanity's most pressing challenges, and we are eager to address this issue in collaboration with PACE and like-minded enterprises within its portfolio."
The program director of PACE, Dr. Beverley Isherwood, applauded InnotiveDx's efforts, remarking, "Congratulations to Innotive Diagnostics! We are pleased to welcome them into the PACE portfolio following a highly competitive funding call for diagnostics. PACE will support InnotiveDx in advancing InnotiveUTI through a collaborative approach, assisting them in generating essential validation data required for further development, financing, and investment for their project."
InnotiveDx is an innovative in vitro diagnostics company focusing on the progression of cutting-edge diagnostic systems, including the InnotiveUTI test that provides comprehensive bacterial identification and AST results at the point of care in just 60 minutes—a service that is currently lacking in many healthcare settings.
PACE stands as one of the UK’s largest public-private initiatives, a collaboration involving Innovate UK, LifeArc, and Medicines Discovery Catapult, dedicated to the early-stage development of antimicrobial drugs and diagnostics. This partnership reflects the collective commitment to revolutionize how urinary tract infections are diagnosed and treated in the face of rising antimicrobial resistance, ensuring timely and accurate interventions for millions affected worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.